ECBio

ECBio is a Portuguese biotechnology company focused on the development of innovative cell-based therapies for regenerative medicine. Founded in 2003, the company specializes in the isolation, expansion, and clinical application of mesenchymal stem cells (MSCs) derived from various human tissues, including bone marrow and umbilical cord. Its lead therapeutic candidate, ECB-001, is an autologous MSC product that has been evaluated in Phase 2 clinical trials for the treatment of critical limb ischemia. In addition to cardiovascular applications, ECBio is advancing a pipeline of regenerative treatments for musculoskeletal conditions, such as bone and cartilage repair. The company leverages its proprietary cell processing platforms and maintains strategic links with the cord blood bank Crioestaminal to bridge the gap between laboratory research and clinical therapy.